Specific findings are as follows: Findings In addition, like vaccination rates for adults, we find wide variation in coverage across the country.
The increase in new doses administered began slowing leading up to the Thanksgiving holiday and has continued since. Overall, we find that after an initial period of high demand, vaccination progress among those ages 5-11 has slowed significantly. Data from Idaho were not available for this age group. We included data from federal entities, territories and associated jurisdictions in our national totals, but only the 50 states and DC in our state analysis. To calculate the number of 5-11 year-olds who had received at least one vaccine dose by state, we calculated the difference between the number of those aged 5+ with at least one dose and the number of those aged 12+ with one dose. Our analysis is based on data obtained from the CDC’s Data Tracker, which itself is based on data reported by jurisdictions to CDC however, there may be differences between the CDC Tracker and data provided on individual state websites due to reporting timeframe and other factors. We previously discussed many of the issues to consider in rolling out pediatric COVID-19 vaccines to the 28 million 5-11 year-olds living in the U.S., including that a new formulation of the vaccine needed to be shipped for this purpose, different vaccine providers would need to be engaged, and parents and caregivers would play the determinate role in the effort, all factors suggesting that rollout might face unique issues. Now, a little more than one month since vaccines were first recommended for kids, we examine progress to date nationally and by state. On November 2, the Centers for Disease Control and Prevention (CDC) recommended Pfizer’s COVID-19 vaccine for children, ages 5-11, in the United States, making the U.S.